The influence of the Centers for Medicare and Medicaid Services (CMS) on healthcare policy and reimbursement is increasing as the US population ages and healthcare reform unfolds. Federal, state and local government healthcare spending is projected to be 50 percent of national health expenditures by 2021. Consequently, the importance of understanding, translating, and engaging CMS and other influential government agencies/groups will only grow.
Best Practices, LLC conducted this research to help biopharmaceutical executives formulate a strategic approach for optimizing engagement with CMS and the ecosystem of agencies and groups that shape U.S. healthcare guidelines and reimbursement policy. The study identifies current trends and future directions in structure, staffing, collaboration, resource allocations, and most-valued group activities across the biopharmaceutical and medical device sector.
The research examines performance excellence by probing how diverse groups such as Government Affairs, Policy, Managed Markets Marketing and other relevant stakeholders are staffed and organized to influence public policy and regulatory issues, particularly those flowing from CMS and other entities in the public sector healthcare system.
The report is based on the insights of 23 leading healthcare companies. Segmentation analysis was key to examining trends and effective practices. Eight participants represent both the Large Pharma Segment (LPS) and Mid-Cap Segment (MPS). The Emerging Segment consists of seven companies. In addition, deep-dive interviews were conducted with six participating companies to gather additional insights.
Key areas of focus will include looking at:
* Proactively Monitoring & Managing Public Sector Healthcare Changes
* Effectiveness of Managing Public Sector Healthcare Changes
* Managing & Shaping U.S. Public Policy Regarding Healthcare
* Managing & Monitoring State-level Government Affairs
* Government Affairs & Public Policy Resources: Staffing and Resource